Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (3817)	2/1/2001 11:00:22 PM
From: RJMC	Read Replies (1) \| Respond to of 5665

Interesting to read about the possible stock manipulation back in the mid-90's. Although it is long behind us, I think many of us who were investing in the company in that time frame felt that something wasn't quite right (even Mitch said so) with the stock. This manipulation may have driven the stock price down significantly and I believe influenced the stock price all the way through until late 1999. It sure would have been a lot easier for the company to get working capital in that time frame had the stock been at a higher value. The deal with Glaxo - Smith Kline may have been a little easier also. Many of us were on pins and needles for a number of years wondering if IMGN would make it through the next payday for its employees. Manipulation of this magnitude in the early inception of a company has a substantial impact that will continue ad infinitum. I hope the SEC sticks it to 'em good. Truthfully, IMGN may not have been forced to issue as many shares as they did at rock bottom prices during that time frame had the price of the stock been higher. Dilution is a tough thing to do at those types of prices. Oh well. Water under the bridge now. Very nice to see that the SEC is on top of those types of things. Bob M.